Are you Dr. Pelletier?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1520 San Pablo St
Suite 3000
Los Angeles, CA 90033Phone+1 323-442-5710Fax+1 203-737-6375
Summary
- Dr. Daniel Pelletier, MD is a neurologist in Los Angeles, California. He is currently licensed to practice medicine in California, Michigan, and Connecticut. He is affiliated with Keck Hospital of USC and USC Norris Comprehensive Cancer Center.
Education & Training
- Laval UnivClass of 1994
Certifications & Licensure
- MI State Medical License 2023 - 2026
- CA State Medical License 1999 - 2024
- CT State Medical License 2011 - 2015
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Vitamin D Supplementation in Multiple Sclerosis Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- Multicenter automated central vein sign detection performs as well as manual assessment for the diagnosis of multiple sclerosis.Abigail R Manning, Vijay Letchuman, Melissa L Martin, Elaina Gombos, Timothy Roberts-Fitzgerald
AJNR. American Journal of Neuroradiology. 2024-09-27 - Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis.Karlo Toljan, Lynn Daboul, Praneeta Raza, Melissa L Martin, Quy Cao
Multiple Sclerosis. 2024-09-01 - Dimethyl fumarate preserves brainstem and cervical spinal cord integrity in radiologically isolated syndrome.Darin T Okuda, Christina J Azevedo, Daniel Pelletier, Tatum M Moog, Saeed Moazami
Journal of Neurology. 2024-09-01
Press Mentions
- MS Treatment Extends Time to First Symptom in Trial in People with Radiologically Isolated Syndrome (RIS)December 15th, 2022
- Repopulation of T, B, and NK Cells Following Alemtuzumab Treatment in Relapsing-Remitting Multiple SclerosisJune 15th, 2020
- Phase 2 Trial Testing NurOwn Therapy for Progressive MS Adds Third Clinical SiteJuly 12th, 2019
- Join now to see all
Other Languages
- French